---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-137089"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2025-06-06T23:59:59+00:00"
generated_at: "2026-05-19T18:03:00.892624+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics gets Nasdaq delisting notice for negative stockholders' equity

## Summary
- Company reported stockholders' equity deficit of $23.6M as of March 31, 2025, failing Nasdaq's $2.5M minimum.
- Nasdaq staff determined to delist securities; company must request a hearing by June 10, 2025.
- Common stock (PSTV) continues trading on Nasdaq Capital Market pending hearing decision.
- Company plans to appeal; hearing typically scheduled 30-45 days after request.
- Previously regained compliance on equity requirement on March 7, 2025, but fell back into non-compliance.

## SEC filing metadata
- accession: 0001193125-25-137089
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2025-06-06T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000119312525137089/0001193125-25-137089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000119312525137089/d39292d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-137089
- JSON: https://secwatch.observer/filing/0001193125-25-137089.json
- Plain text: https://secwatch.observer/filing/0001193125-25-137089.txt

## Key facts
- Listing & Compliance Notices
  PLUS THERAPEUTICS, INC. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: June 3, 2025, Plus Therapeutics, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the Rule 5250(c)(1) due to filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “Quarterly Report”) with the U.S. Securities and Exchange Commission (the “SEC”) on May 30, 2025. As previously disclosed, on March 8, 2024, the Company received a written notice from the Staff, notifying the Company that it no longer complied with the requir
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312525137089/0001193125-25-137089-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.